Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBITDA (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBITDA for 16 consecutive years, with -$7.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 140.99% to -$7.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.4 million, a 81.27% decrease, with the full-year FY2024 number at $33.1 million, down 47.43% from a year prior.
  • EBITDA was -$7.1 million for Q3 2025 at Usana Health Sciences, down from $13.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $41.8 million in Q3 2021 to a low of -$7.1 million in Q3 2025.
  • A 5-year average of $15.8 million and a median of $13.8 million in 2025 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 118.86% in 2023, then plummeted 140.99% in 2025.
  • Usana Health Sciences' EBITDA stood at $26.8 million in 2021, then dropped by 25.38% to $20.0 million in 2022, then increased by 16.43% to $23.3 million in 2023, then plummeted by 119.39% to -$4.5 million in 2024, then tumbled by 58.05% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's EBITDA are -$7.1 million (Q3 2025), $13.8 million (Q2 2025), and $9.2 million (Q1 2025).